Vernakalant HCl, formerly known as RSD1235, is an investigational drug for the acute conversion of atrial fibrillation. Like other class III antiarrhythmics, vernakalant blocks atrial potassium channels, thereby prolonging repolarization. It differs from typical class III agents by blocking a certain type of potassium channel, the cardiac transient outward potassium current, with increased potency as the heart rate increases. This means that it is more effective at high heart rates, while other class III agents tend to lose effectiveness under these circumstances. It also slightly blocks the hERG potassium channel, leading to a prolonged QT interval. Vernakalant also blocks atrial sodium channels. References: Frommeyer G, Ellermann C, Dechering DG, Kochhauser S, Bogeholz N, Güner F, Leitz P, Pott C, Eckardt L. Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome. J Cardiovasc Electrophysiol. 2016 Jun 10. doi: 10.1111/jce.13029. [Epub ahead of print] PubMed PMID: 27283775.

纯度：≥98%

CAS：748810-28-8